BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 02/13/24

BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum PR Newswire NEW YORK , Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disea...

NEW YORK, NY / ACCESSWIRE / February 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or "the Company") (NASDAQ:BCLI). Investors who purchased Brainstorm Cell securities prior to Aug...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 ...

2023-12-26 10:14:39 ET DENVER, Colo., Dec. 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Inspira Technologies Oxy BHN Ltd (NASDAQ: IINN), Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI), 60 Degrees ...

2023-12-26 09:12:31 ET DENVER, Colo., Dec 26, 2023 ( www.247marketnews.com )- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) provided an update, this morning, on the grant and allowance of three patent applications for NurOwn and NurOwn-Exosomes, by the European Patent office, includi...

2023-12-26 08:19:44 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript BrainStorm, FDA to discuss regulatory path forward for ALS therapy Brainstorm realigns resources to support NurOwn development ...

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments PR Newswire NEW YORK , Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for n...

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS PR Newswire Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK , Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a le...

2023-11-20 10:57:50 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...